| Company Name: |
Chemleader Biomedical Co., Limited. Gold
|
| Tel: |
021-58180488 |
| Email: |
sales@MedChemLeader.com |
| Products Intro: |
Product Name:N-(3-fluoro-4-((7-(2-hydroxy-2-methylpropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 4-methylbenzenesulfonate;Ningetinib Tosylate (CT-053 Tosylate)
CAS:1394820-77-9
Purity:98%+ Package:500mg;1g;5g;10g Remarks:Pharmaceutical Intermediates
|
Ningetinib Tosylate manufacturers
|
| | Ningetinib Tosylate Basic information |
| Product Name: | Ningetinib Tosylate | | Synonyms: | N-(3-fluoro-4-((7-(2-hydroxy-2-Methylpropoxy)quinolin-4-yl)oxy)phenyl)-1,5-diMethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxaMide p-toluenesulfonate;N-(3-Fluoro-4-((7-(2-hydroxy-2-methylpropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-ph;1H-Pyrazole-4-carboxamide, N-[3-fluoro-4-[[7-(2-hydroxy-2-methylpropoxy)-4-quinolinyl]oxy]phenyl]-2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-, 4-
methylbenzenesulfonate (1:1);112176;CT-053;Ningetinib-Tosylate(tosylate);CT-053 tosylate;Ningetinib Tosylate (CT-053 Tosylate) | | CAS: | 1394820-77-9 | | MF: | C38H37FN4O8S | | MW: | 728.7857832 | | EINECS: | | | Product Categories: | | | Mol File: | 1394820-77-9.mol |  |
| | Ningetinib Tosylate Chemical Properties |
| storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | DMSO: 33.33 mg/mL (45.73 mM); Water: < 0.1 mg/mL (insoluble) | | form | Solid | | color | White to off-white | | InChIKey | NAUYISNCVNUUDK-UHFFFAOYSA-N | | SMILES | N1(C)C(C)=C(C(NC2=CC=C(OC3=C4C(=NC=C3)C=C(OCC(O)(C)C)C=C4)C(F)=C2)=O)C(=O)N1C1=CC=CC=C1.C1(S(O)(=O)=O)=CC=C(C)C=C1 |
| | Ningetinib Tosylate Usage And Synthesis |
| Uses | Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively. | | in vivo | When single dosed orally (3 mg/kg) to U87MG tumor-bearing nude mice, Ningetinib Tosylate (CT053PTSA) potently inhibits the phosphorylation of c-Met and its downstream signaling kinases AKT and ERK1/2 for up to 6 hours in tumor tissues. In orthotopic U87MG human glioblastoma xenograft model, Ningetinib Tosylate prolongs the median survival time (MST) and yields significant increase in life-span value (ILS=32%, p=0.003) at an oral dose of 20 mg/kg/day (dosed 21 days) versus the vehicle-treated group[1]. | | IC 50 | Axl; VEGFR2: 1.9 nM (IC50) | | References | [1] Ning Xi, et al. Abstract 1755: CT053PTSA, a novel c-MET and VEGFR2 inhibitor, potently suppresses angiogenesis and tumor growth. Cancer Res 2014;74(19 Suppl):Abstract nr 1755. |
| | Ningetinib Tosylate Preparation Products And Raw materials |
|